Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUMIT VERMA

Allopathic & Osteopathic Physicians Internal Medicine Clinical Cardiac Electrophysiology

NPI
1225038557
CMS profile
10360
Location
PENSACOLA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$20,467.50

91 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUMIT VERMA

NPI 1225038557 · CMS profile ID 10360

Allopathic & Osteopathic Physicians / Internal Medicine / Clinical Cardiac Electrophysiology

PENSACOLA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1225038557?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUMIT VERMA, NPI 1225038557, CMS profile ID 10360. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1225038557?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SUMIT VERMA, NPI 1225038557, CMS profile ID 10360. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1225038557?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SUMIT VERMA, NPI 1225038557, CMS profile ID 10360, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1225038557?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

91 matching records · $20,467.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 91 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–91 of 91.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CVRx, Inc. $70.2006/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138737260 CMS
CVRx, Inc. $527.1905/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123810570 CMS
CVRx, Inc. $294.5205/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124866483 CMS
CVRx, Inc. $260.3405/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124866487 CMS
CVRx, Inc. $39.6005/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138737258 CMS
Abbott Laboratories $180.6105/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124907218 CMS
Cook Medical LLC $56.6205/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117467808 CMS
Abbott Laboratories $476.2905/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125396061 CMS
Abbott Laboratories $9.0205/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125396081 CMS
CVRx, Inc. $171.5505/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138737256 CMS
Abbott Laboratories $381.9405/15/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155259303 CMS
Boston Scientific Corporation $135.7405/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092413574 CMS
Abbott Laboratories $140.0805/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124907216 CMS
PFIZER INC. $18.5005/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131357148 CMS
Abbott Laboratories $9.2305/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124907214 CMS
iRhythm Technologies, Inc. $18.6905/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154043093 CMS
Boston Scientific Corporation $13.2705/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092413568 CMS
Philips North America LLC $43.9004/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146887966 CMS
Abbott Laboratories $4.9104/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124907212 CMS
CORDIS US CORP. $15.8703/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145407519 CMS
Philips North America LLC $90.6503/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146887972 CMS
Philips North America LLC $5.8603/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146887960 CMS
CVRx, Inc. $19.1603/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138737252 CMS
CVRx, Inc. $165.2703/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138737254 CMS
Baxter Healthcare $39.6403/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120585911 CMS
Philips North America LLC $7.4803/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146887964 CMS
Philips North America LLC $64.6502/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146887956 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $79.0202/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080704444 CMS
Philips North America LLC $41.0002/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146887942 CMS
Philips North America LLC $7.2902/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146887952 CMS
Philips North America LLC $7.2902/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146887954 CMS
Medtronic, Inc. $88.7502/12/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247172411 CMS
iRhythm Technologies, Inc. $16.0302/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154043091 CMS
Abbott Laboratories $41.8502/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124907210 CMS
Boston Scientific Corporation $143.6202/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092413576 CMS
Philips North America LLC $41.0001/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146887944 CMS
Philips North America LLC $618.7501/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146887946 CMS
Philips North America LLC $8.2401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146887948 CMS
Philips North America LLC $8.2401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146887950 CMS
iRhythm Technologies, Inc. $17.1701/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154043075 CMS
PFIZER INC. $13.6301/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130972734 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,242.97 50
PY2020 $6,195.47 16
PY2021 $5,361.87 29
PY2022 $7,422.17 59
PY2023 $11,331.04 81
PY2024 $20,467.50 91
PY2025 $20,169.06 107

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $97,578.00 29
PY2024 Principal investigator $178,269.00 28
PY2023 Principal investigator $67,541.16 10
PY2020 Principal investigator $1,175.00 5
PY2019 Principal investigator $950.00 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $3,085.00 12/12/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175198992
Principal investigator 1 Janssen Research & Development, LLC $4,027.00 11/19/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199246
Principal investigator 1 Janssen Research & Development, LLC $6,745.00 11/07/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199192
Principal investigator 1 Janssen Research & Development, LLC $1,080.00 11/03/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199311
Principal investigator 1 Janssen Research & Development, LLC $456.00 10/08/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199096
Principal investigator 1 Medtronic, Inc. $1,575.00 10/03/2025 Non-covered Recipient Entity
Baptist Health Care Corporation
ALLEVIATE-HF No dispute reported 06/30/2026 1192325379
Principal investigator 1 Janssen Research & Development, LLC $2,338.00 10/02/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175198981
Principal investigator 1 Medtronic, Inc. $3,150.00 09/26/2025 Non-covered Recipient Entity
Baptist Health Care Corporation
ALLEVIATE-HF No dispute reported 06/30/2026 1192325377
Principal investigator 1 Janssen Research & Development, LLC $514.00 09/24/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199319
Principal investigator 1 Janssen Research & Development, LLC $7,453.00 09/19/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199116
Principal investigator 1 Medtronic, Inc. $1,000.00 09/05/2025 Non-covered Recipient Entity
Baptist Health Care Corporation
ALLEVIATE-HF No dispute reported 06/30/2026 1192325371
Principal investigator 1 Medtronic, Inc. $1,000.00 09/05/2025 Non-covered Recipient Entity
Baptist Health Care Corporation
ALLEVIATE-HF No dispute reported 06/30/2026 1192325373
Principal investigator 1 Medtronic, Inc. $533.00 08/29/2025 Non-covered Recipient Entity
Baptist Health Care Corporation
ALLEVIATE-HF No dispute reported 06/30/2026 1192325375
Principal investigator 1 Janssen Research & Development, LLC $6,214.00 08/25/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199277
Principal investigator 1 Janssen Research & Development, LLC $2,168.00 08/01/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199222
Principal investigator 1 Janssen Research & Development, LLC $8,576.00 07/23/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175198974
Principal investigator 1 Janssen Research & Development, LLC $1,936.00 06/23/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199305
Principal investigator 1 Janssen Research & Development, LLC $6,606.00 06/20/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199068
Principal investigator 1 Medtronic, Inc. $180.00 06/13/2025 Non-covered Recipient Entity
Baptist Health Care Corporation
ALLEVIATE-HF No dispute reported 06/30/2026 1192325369
Principal investigator 1 Janssen Research & Development, LLC $1,726.00 05/21/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199181
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 05/19/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199269
Principal investigator 1 Janssen Research & Development, LLC $10,888.00 04/23/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199237
Principal investigator 1 Medtronic, Inc. $2,000.00 03/28/2025 Non-covered Recipient Entity
Baptist Health Care Corporation
ALLEVIATE-HF No dispute reported 06/30/2026 1192325367
Principal investigator 1 Janssen Research & Development, LLC $2,876.00 03/21/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199230
Principal investigator 1 Janssen Research & Development, LLC $456.00 03/14/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199252
Principal investigator 1 Janssen Research & Development, LLC $8,235.00 02/19/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199038
Principal investigator 1 Janssen Research & Development, LLC $456.00 02/05/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199000
Principal investigator 1 Janssen Research & Development, LLC $465.00 01/24/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199016
Principal investigator 1 Janssen Research & Development, LLC $10,340.00 01/22/2025 Non-covered Recipient Entity
Bapt Hlth Care Infusion Centers
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175199053